<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397475</url>
  </required_header>
  <id_info>
    <org_study_id>142/06</org_study_id>
    <nct_id>NCT00397475</nct_id>
  </id_info>
  <brief_title>Evaluation of Colecalciferol Substitution in Dialysis Patients</brief_title>
  <official_title>Evaluation of Colecalciferol Substitution in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a colecalciferol substitution in
      dialysis patients on bone metabolism and immune system
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD14/CD16-Monocyte-Subsets (Frequency)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production of Cytokines: IFN-γ, TNF-α</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Calcium, Phosphorus, iPTH, hsCRP, alkaline phosphatase</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th1/Th2- and Tc1/Tc2-Lymphocyte-Frequency</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>RENAL INSUFFICIENCY, CHRONIC</condition>
  <condition>Hyperparathyroidism, Secondary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colecalciferol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Serum 25-OH-Vit.D-levels &lt; 60 ng/ml

          2. Age &gt; 18 years

          3. dialysis treatment &gt; 3 Months

          4. signed written informed consent

          5. Serum-Calcium-levels &lt; 2,6 mmol/l within the last 4 weeks

          6. Serum-Phosphate-levels &lt; 7,0 mg/dl within the last 4 weeks

          7. Ca x P-Product &lt; 75 mg2/dl2 within the last 4 weeks

        Exclusion Criteria:

          1. Serum 25-OH-Vit.-D-levels &gt; 60 ng/ml

          2. concommitant participation in another interventional trial

          3. psychiatric disorders preventing from valid informed consent

          4. Hyperphosphatemia (&gt; 7,0 mg/dl) within the last 4 weeks

          5. Hypercalcemia (&gt; 2,6 mmol/l) within the last 4 weeks

          6. Ca x P-Product &gt; 75 mg2/dl2 within the last 4 weeks

          7. pregnancy or lactation

          8. known malignancy

          9. liver disease, defined as 2-fold upper limit of ASAT-, or ALAT-levels

         10. PTH levels &lt; 50 pg/ml

         11. current clinically relevant infections treated with antibiotic therapy and raised
             hsCRP levels

         12. Chronic viral Infectious diseases (e.g. HIV, Hepatitis B or C)

         13. Immunosuppressant Medication

         14. known hematologic disorders, other than renal anemia

         15. age below 18 years

         16. known anaphylactic reaction against the study medication or other ingredients of the
             study drug preparation

         17. renal calculus

         18. Pseudohypoparathyroidism

         19. Medication including cardiac glycosides

         20. Sarkoidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Seibert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

